Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

By Carsten Denkert, S. Loibl, A. Noske, M. Roller, B. Müller, M. Komor, Jan Budczies, S. Darb-Esfahani, R. Kronenwett, C. Hanusch and 7 more. Journal of Clinical Oncology, 2010

1,620 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/dca123f458f93f7bd608a7e6ec5e01bbab1dadfe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation (2017, background): “The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
Clinical significance of tumor-infiltrating lymphocytes in breast cancer (2016, background): “Infiltration of immune cells, particularly infiltration of anti-tumor type 1 lymphocytes, has predicted improved prognosis in many different tumor types including colon, ovarian, lung and breast cancer [1 – 4].”
The immune contexture in human tumours: impact on clinical outcome (2012, background): “, a cancer type in which a high lymphocyte infiltrate is associated with a higher response rate to neoadjuvant therap”
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. (2013, neutral): “Additionally, two recent studies demonstrated that a higher immune score in the initial biopsy predicts increased pCR rates after preoperative chemotherapy (88), with the strongest association observed in the HER2 + and ER – /HER2 – subtypes (44).”
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. (2014, neutral): “(%) 2007–2008 7 (7) 3217 (8) (54–56,59,78,81,107) 2009–2010 17 (17) 3982 (10) (39,42,48,51,58,60,68,73,80,84,86,87,95,97,99,101,103) 2011 19 (19) 4614 (11) (33,40,49,52,62,63,66,69,79,83,96,98, 104,118,121,124,125,131,132) 2012 38 (38) 23 840 (59) (34,43,44,46,47,50,53,57,61,64,65,67,71,72,74–77,88,”
Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment (2019, background): “Analyses from neoadjuvant and adjuvant TNBC trials have shown that tumor-infiltrating lymphocytes (TIL), assessed by hematoxylin–eosin staining, are predictive of response to therapy and strongly associated with improved survival (107, 108).”
Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…shortened OS De Monte et al., 2011 TH2 cells GATA3 + TILs CD3+ breast carcinoma neoadjuvant chemotherapy increased amounts of TILs predicted pCR Denkert et al., 2010 GIST adjuvant imatinib-based chemotherapy high levels of TILs correlated with improved PFS Rusakiewicz et al., 2013 melanoma…”
Cancer classification using the Immunoscore: a worldwide task force (2012, background): “Data based on immune signatures have established that a strong immune component is predictive of good response to chemotherapy in breast cancer [31-33], a tumor in which a high lymphocyte infiltrate is associated with higher response rate in neo-adjuvant therapy [34,35].”
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 (2011, background): “In neoadjuvant therapy, a stromal signature is associated with a reduced response, while a lymphocytic infiltrate predicts for a higher response rate [38, 39].”
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. (2014, methodology): “Evaluation of the quantity and location of TILs (stromal and intratumoral) was carried out exactly as previously described on fullface hematoxylin and eosin-stained (H&E) sections [4, 7].”